Broad Institute

MAY 9, 2024

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery.

Clinical Trials 52

Clinical Trials Clinical Development Disease Science 52

The Pharma Data

OCTOBER 9, 2021

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About LATTICE-UC.

Disease 52

Disease Trials Science Immune Response 52

Vial

MARCH 1, 2024

The growing demand for CRO services is fueled by the high costs of in-house drug discovery and development, the increasing number of products in the development pipeline, tech advancements, and the growing focus on precision and personalized medicine. billion by 2029. from 2024 to reach US$129.8 completed its acquisition of PPD.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

JANUARY 25, 2021

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52